Avinger, Inc. (NASDAQ:AVGR) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the Avinger Third Quarter 2024 Results Conference Call. At this time, all participants are on a listen-only mode. After managements prepared remarks, there will be a question ...

Avinger (AVGR) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.03. This compares to loss of $2.92 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.34%. A quarter ago, it was expected that this medical device maker would post a loss of $0.43 per share when it actually produced a loss of $2.82, delivering a surprise of -555.81%. Over the last four quarters, the company has ...

Exhibit 99.1 Avinger Reports Third Quarter 2024 Results Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin Redwood City, Calif., November 7, 2024 - Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024. Third Quarter and Recent Highlights ● Reported ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class: Trading Symbol(s): Name of each exchange on which registered: Common Stock, par value $0.001 per share AVGR The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36 ...

Avinger, Inc. (AVGR) has announced the full commercial launch of its Pantheris LV image-guided directional atherectomy system. It is the first and only image-guided system for treating peripheral artery disease (PAD) in large vessels.The Pantheris LV builds upon the success of Avinger’s Pantheris SV, expanding its application to above-the-knee procedures with advanced features that enhance both performance and usability.Significance of Pantheris LVPer Avinger, the full commercialization of Pantheris LV mark ...

Avinger, Inc. (NASDAQ:AVGR) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Matt Kreps - Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Welcome to the Avinger Second Quarter 2024 Results Call. At this time, all participants are on a listen-only mode. Later we’ll conduct a question-and-answer session. I'll now turn the call over to your host, ...

Avinger (AVGR) came out with a quarterly loss of $2.82 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $8.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -555.81%. A quarter ago, it was expected that this medical device maker would post a loss of $1.35 per share when it actually produced a loss of $2.49, delivering a surprise of -84.44%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class: Trading Symbol(s): Name of each exchange on which registered: Common Stock, par value $0.001 per share AVGR The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36817 A ...

Exhibit 99.1 Avinger Reports Second Quarter 2024 Results Implements Lower Operating Cost Profile, Readying OCT-Guided Coronary Device for IDE Submission Redwood City, Calif., August 8, 2024 - Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Avinger (AVGR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Avinger is one of 1048 individual stocks in the Medical sector. Collectively, these compan ...